Dr. Angela Cheng-Lai has a strong interest in cardiovascular pharmacotherapy and focuses many of her clinical activities and publications in this area. She is a pharmacology section editor and writer for the journal Cardiology in Review. In addition, she is passionate about the pharmacy profession and she has been a clinical pharmacist at Montefiore Health System for more than 20 years. She is currently the Director of Communications at the New York State Council of Health-System Pharmacists.

1. Al-Bawardy R, Cheng-Lai A, Prlesi L, Assafin M, Xu S, Chen K, Tandan S, Aneke CS, Murthy S, Piña IL. Heart Failure Postdischarge Clinic: A Pharmacist-led Approach to Reduce Readmissions. Curr Probl Cardiol. 2019 Oct;44(10):100407. doi: 10.1016/j.cpcardiol.2018.12.004. Epub 2019 Jan 5
2. Cheng-Lai A, Snead J, Ng C, Verges C, Chung P. Comparison of adherence to  the 2013 ACC/AHA cholesterol guideline in a teaching versus non-teaching outpatient clinic. Ann Pharmacother. 2018; 52(4): 338-344.
3. Chan J, Cheng-Lai A. Inhaled Insulin: A clinical and historical review. Cardiol Rev 2017;25(3):140-146.
4. Ng C, Chung P, Toderika Y, Cheng-Lai A. Evaluation of adherence to current guidelines for treatment of hyperlipidemia in adults in an outpatient setting. Am J Health-Syst Pharm 2016;73(23 Supplement 6):S133-S140.
5. Vu BN, DeCastro AM, Shottland D, Frishman WH, Cheng-Lai A. Patiromer: The first potassium binder approved in over 50 years. Cardiol Rev 2016;24(6):316-323.
6. Patel BB, Feng Y, Cheng-Lai A. Pulmonary Arterial Hypertension: A Review in Pharmacotherapy.  Cardiology in Review 2015;23:33-51.
7. Chowdhury M, Wong J, Cheng A, Khilkin M, Palma E. Methadone therapy in underserved urban community: QTC prolongation and life-threatening ventricular arrhythmias. Cardiovasc Ther  2015;33(3):127-33.
8. Lam S, Nawarskas J, Cheng-Lai A: Chapter 16: Anemia and Preventive Therapy. In, Fundamentals of Geriatric Pharmacotheray: An Evidence-Based Approach, 2nd ed. Bethesda, American Society of Health-System Pharmacists, 2015.
9. Cheng-Lai A: Chapter 3: The pharmacist’s role in caring for patients with heart failure. In, Heart failure: Strategies to improve outcomes.  Cardiotext Publishing, Minneapolis, 2013.
10. Frishman WH, Aronow WS, Cheng-Lai A: Cardiovascular drug therapy in the elderly.  In Aronow WS, Fleg JL, Rich MW (eds): Cardiovascular Disease in the Elderly, 5th ed.  New York: Informa, 2013.
11. Goswami S, Cheng-Lai A. Clopidogrel and genetic testing: Is it necessary for everyone? Cardiology in Review 2012;20:96-100.
12. Curzio KM, Cheng-Lai A, Kheyfets V, Sinnet M, Billett HH. A comparison of direct thrombin inhibitors in the treatment of heparin-induced thrombocytopenia: a single institution experience. J Thromb Thrombolysis 2009;28(2):117-23.
13. Cheng-Lai A, Nawarskas J, Frishman WH (eds): Hypertension: A Clinical Guide, Philadelphia: Wolters Kluwer Health, 2007.
14. Shprecher AR, Cheng-Lai A, Madsen EM, Cohen HW, Sinnett MJ, Wong ST, Billett HH. Peak antifactor Xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. Pharmacotherapy 2005;25(6):817-822.
15. Frishman WH, Cheng-Lai A, Nawarska J (eds): Current Cardiovascular Drugs, 4th ed.  Philadelphia: Current Medicine, 2005.
16. Cheng-Lai A, Frishman WH. Sirolimus-eluting coronary stents: novel devices for the management of coronary artery disease. Am J Ther 2004; 11:218-228.
17. Frishman WH, Cheng A. Secondary prevention of myocardial infarction: Role of β-adrenergic blockers and angiotensin-converting enzyme inhibitors. Am Heart J 1999;137:S25-S34.